Senhwa's CX-5461 Reaches Immuno-Oncology Milestone as its First Multicenter Combination Trial with PD-1 Inhibitor Receives TFDA Clearance

RegulatoryapprovedpidnarulexPositive

AI Analysis

Summary

Senhwa Biosciences announced that Taiwan's FDA cleared a Phase 1b/2a multicenter trial evaluating its investigational drug pidnarulex (CX-5461) in combination with a PD-1 inhibitor for immuno-oncology indications.

Clinical Trial Data

Phase

1b/2a

Outcome Details

Taiwan Food and Drug Administration cleared multicenter Phase 1b/2a clinical trial of pidnarulex in combination with PD-1 inhibitor

Importance:6/10

Sentiment:

0.70

immuno-oncologycombination therapyPD-1 inhibitorclinical trialregulatory clearanceTaiwan

Related Companies

$INTI $DFPH $TRAX

Read the original article

Published by PR Newswire Biotech on August 6, 2026 9:14 AM

Read Original